Clinical Utility of C-Reactive Protein Measured at Admission, Hospital Discharge, and 1 Month Later to Predict Outcome in Patients With Acute Coronary DiseaseThe RISCA (Recurrence and Inflammation in the Acute Coronary Syndromes) Study
Peter Bogaty, MD*,*,
Luce Boyer, RN*,
Serge Simard, MSc*,
Franz Dauwe, MD ,
Robert Dupuis, MD ,
Benoît Verret, MD ,
Thao Huynh, MD||,
Fernand Bertrand, BSc*,
Gilles R. Dagenais, MD, FACC* and
James M. Brophy, MD, PhD, FACC¶
* Quebec Heart Institute/Laval Hospital, Laval University, Quebec City, Quebec, Canada
Complexe hospitalier de la Sagamie, Chicoutimi, Quebec, Canada
Centre hospitalier de la région de l'Amiante, Thetford-Mines, Quebec, Canada
Centre hospitalier régional du Grand-Portage, Rivière-du-Loup, Quebec, Canada
|| Montreal General Hospital, McGill University Health Center, Montreal, Quebec, Canada
¶ Hôpital Notre Dame, University of Montreal and McGill University Health Center, Montreal, Quebec, Canada.

View larger version (32K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Selection of Study Cohort
Flow diagram of screened patients admitted with chest pain, depicting reasons for exclusions in selection of study cohort. *Excludes any patients who died before they could be approached for this study. **In some centers.
|
|

View larger version (26K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 CRP Values in Patients With and Without Events
The C-reactive protein (CRP) values at admission, at hospital discharge, and at 1 month after discharge in patients with and without occurrence of the primary outcome (death, myocardial infarction [MI] by troponin definition, or unstable angina [UA] with electrocardiographic changes) and its individual components.
|
|
|